Submission of outcome of Board Meeting held inter alia to consider Audited Financial Results for the quarter and year ended 31 March 2025

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹67.02

prior close

₹67.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.3% vs market

Pharmaceuticals peers, median of 147sector-0.1%+1.5% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+6.6

10m

+6.5

15m

+3.6

30m

+4.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.1+1.3-0.1+1.5

Next day

-1.6-0.2-1.4-0.2-1.5

-4.9+0.3-5.2-0.2-4.6

-3.9+0.9-4.7+0.0-3.9

-5.5+0.8-6.2+0.0-5.5

-1.8+2.2-4.0+0.6-2.5

-7.9+3.4-11.3+1.4-9.4

15d

-16.4-0.8-15.7-2.9-13.5

-9.2+2.9-12.1+0.3-9.5

-15.0+0.8-15.9-0.4-14.7

-21.0+0.0-21.0-3.2-17.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Roopa Industries Limited reported strong full-year FY25 results with revenue from operations rising to ₹12,068.70 lakhs from ₹7,042.62 lakhs in FY24, a growth of about 71%. Profit after tax grew to ₹203.49 lakhs (₹2.57 EPS) from ₹151.91 lakhs (₹1.95 EPS), up roughly 34% year-on-year. For Q4 alone, revenue grew about 35% to ₹2,983.27 lakhs but PAT dipped slightly to ₹41.80 lakhs from ₹45.52 lakhs. Statutory auditors Yelamanchi & Associates issued an unmodified opinion on the results. The Board also appointed Geeta Serwani & Associates as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30, subject to shareholder approval. Operating cash flow turned sharply negative at -₹659.36 lakhs versus +₹200.98 lakhs in FY24, mainly due to a big jump in inventory and receivables.

Likely market impact

Strong top-line and PAT growth for the full year is positive for shareholders, though the negative operating cash flow and slight Q4 PAT softness are minor concerns. The clean audit opinion and routine auditor appointment are neutral to positive signals.